Clinical significance of lineage crossover in leukernic cells
Clinical significance of lineage crossover in leukernic cells
批准号:
11672292
负责人:
OHTAKE Shigeki
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2001
中文摘要
1.采用半套式聚合酶链式反应和聚丙烯酰胺凝胶电泳法对40例初治急性髓系白血病患者的白血病细胞免疫球蛋白重链基因重排的互补决定区3(CDR3)进行了分析。34例患者(85%)检测到克隆性IgH基因重排。对克隆性重排患者的IgH基因CDR3DNA序列进行分析。在分析的46个序列中,有30个序列(65%)具有共同序列。该序列为5‘ATTACTAGATA3’。已在互联网上的V-Base数据库中注册为“D3-22”。目前还没有澄清这种现象是如何产生的,以及它具有什么样的生物学意义。针对重组激活基因开发的进一步研究可能会澄清这一现象。我们在B淋巴系恶性肿瘤患者血清DNA中发现克隆性IgH基因重排。可望将该方法应用于淋巴样恶性肿瘤的临床实验室检查。
英文摘要
1. We have analyzed complementarity-determining region 3(CDR3) of immunoglobulin heavy (IgH) chain gene rearrangement in leukerhic cells fron 40 untreated acute myeloid leukemia patients using semi-nested PCR method and polyacrylamide gel electrophoresis.2. Clonal IgH gene rearrangement was detected in 34 patients (85%).3. IgH gene CDR3 DNA sequence was analyzed in patients showing clonal rearrangement. Thirty sequences (65%) out of 46 analyzed had common sequence.4. This sequence was 5 'ATTACTAGATA3 ' and has. Been registered as "D3-22" in V-Base Database in the Internet.5. It was not clarified how this phenomenon was caused and what kind of biological significance it had. Further research focusing recombination activating gene development may clarify this phenomenon.6. We have found clonal IgH gene rearrangement in DNA from serum of patients with B lymphoid malignancy. It is anticipated that the application of this method in clinical laboratory examination in the case of Blymphoid malignancy.
期刊论文(34)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
大竹 茂樹: "急性骨髄性白血病"臨床成人病. 30・4. 480-484 (2000)
大竹茂树:“急性髓性白血病”临床成人疾病。30・480-484(2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Okumura H: "CD8-deplet ed donor leukocyte transfusions for cytomegalovirus antigenemia in patient with acute lymphoblastic leukemia treated with allogeneic CD34(+) cell transplantation"Am J Hematol. 65・4. 278-280 (2000)
Okumura H:“用同种异体 CD34(+) 细胞移植治疗的急性淋巴细胞白血病患者的巨细胞病毒抗原血症输注”Am J Hematol 65・4 (2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
大竹 茂樹: "急性骨髄性白血病の治療"内科. 84・3. 460-46 (1999)
大竹繁树:《急性髓系白血病的治疗》《内科》84・3(1999)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Okumura H, Ohtake S, et al: "CD8-depleted donor leukocyte transfusions for cytomegalovirus antigenemia in patient with acute lymphoblastic leukemia treated with allogeneic CD34(+) cell transplantation"Am J Hematol. 65-4. 278-280 (2000)
Okumura H、Ohtake S 等人:“用同种异体 CD34( ) 细胞移植治疗的急性淋巴细胞白血病患者的巨细胞病毒抗原血症的 CD8 耗尽供体白细胞输注”Am J Hematol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ohnishi K, Ohtake S, et al: "Multicenter prospective study of interferon-alpha versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia : a preliminary analysis"Cancer Chemother Pharmacol. 48-S1. 59-64 (2001)
Ohnishi K、Ohtake S 等人:“针对新诊断的慢性粒细胞白血病患者的干扰素 α 与骨髓移植的多中心前瞻性研究:初步分析”Cancer Chemother Pharmacol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 24 条
Establishment of tumor maker test using tumor-derived nucleic acids in plasma
-
批准号:14572177
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.86万
-
财政年份:2002
-
负责人:OHTAKE Shigeki
-
依托单位:
海外基金